Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avdoralimab in antihistamine-resistant chronic spontaneous urticaria
2020-002510-40Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avdoralimab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: UAS7. Started Oct 2020; status: terminated.
02
Drugs
avdoralimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2020-002510-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002510-40.